Imatinib Stada (Imatinib)

Imatinib blocks the activity of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases by binding to their ATP‑binding sites. This inhibition stops downstream signaling that promotes malignant cell growth, leading to reduced proliferation and increased apoptosis of cancer cells.

The dose of Imatinib Stada is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional should determine the appropriate regimen.

The safety of Imatinib Stada in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and clinicians generally advise avoiding use unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor approved and remains a standard of care for CML, Ph+ ALL and GIST. Newer agents may offer activity against specific resistance mutations, but imatinib’s long‑term safety profile and extensive clinical experience make it a widely used first‑line option.

Imatinib Stada should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the tablet shows signs of damage.

Imatinib Stada is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing and any dietary considerations.

Serious risks include hepatic toxicity, severe neutropenia, cardiac failure, pulmonary hypertension, tumor lysis syndrome and anaphylactic reactions. Patients should be monitored regularly for these events, and any concerning symptoms should prompt immediate medical evaluation.

Imatinib Stada is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with pre‑existing liver disease, severe cardiac conditions, or uncontrolled infections, and it should be avoided in pregnant or nursing women unless absolutely necessary.